DDInter856 DDInter518
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn.
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Metamfetamine
Dexfenfluramine {u} (Compound) resembles {v} (Compound) Fenproporex
Dexfenfluramine {u} (Compound) binds {v} (Gene) SLC6A4
Dexfenfluramine {u} (Compound) upregulates {v} (Gene) ARL4C
Dexfenfluramine {u} (Compound) downregulates {v} (Gene) TIMM9
Dexfenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dacomitinib
Dexfenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pioglitazone
Dexfenfluramine {u} may lead to a major life threatening interaction when taken with {v} Sibutramine
Dexfenfluramine may lead to a major life threatening interaction when taken with Metamfetamine
Dexfenfluramine (Compound) resembles Fenproporex (Compound)
Dexfenfluramine (Compound) binds SLC6A4 (Gene)
Dexfenfluramine (Compound) upregulates ARL4C (Gene)
Dexfenfluramine (Compound) downregulates TIMM9 (Gene)
Dexfenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Dexfenfluramine may lead to a major life threatening interaction when taken with Sibutramine